Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
Joan Khoo, Christopher K Rayner, Karen L Jones, Michael Horowitz
Discipline of Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Abstract: The advent of ‘incretin‑based therapies’ – GLP‑1 agonists and dipeptidyl‑peptidase‑4 inhibitors – which result in improvements in glycemic control comparable to those with existing oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic β‑cell function, represents a major therapeutic advance in the management of type 2 diabetes. Gastrointestinal adverse effects occur commonly with GLP‑1 agonists, and rarely with DPP‑4 inhibitors, but are dose‑dependent and usually transient. The low risk of hypoglycemia, and beneficial or neutral effects on body weight, render GLP‑1 agonists and DPP‑4 inhibitors suitable alternatives to insulin secretagogues and insulin in overweight and elderly patients. Incretin‑based therapies also improve quality of life in patients with type 2 diabetes, and may be cost‑effective in the long term.
Keywords: incretin, type 2 diabetes, therapy, GLP‑1, DPP‑4
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]